Trial · NCT03193190
Participant flow128
How many started, completed or left each group, period by period.
1 to 20 of 128
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Stage 1 | STARTED | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 35 | |
| Stage 1 | STARTED | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 9 | |
| Stage 1 | STARTED | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 25 | |
| Stage 1 | STARTED | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 16 | |
| Stage 1 | STARTED | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tiragolumab | 42 | |
| Stage 1 | STARTED | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Tocilizumab | 31 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Control (5-fluorouracil + Leucovorin + Oxaliplatin [mFOLFOX6]) | 25 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Control (Nab-Paclitaxel and Gemcitabine) | 25 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Atezolizumab + BL-8040 | 16 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Atezolizumab + Cobimetinib | 15 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Atezolizumab + PEGPH20 | 71 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 3 Weeks (Q3W) | 16 | |
| Stage 1 | STARTED | Stage 1 Cohort 2: Atezolizumab + RO6874281 Every 2 Weeks (Q2W) | 15 | |
| Stage 1 | STARTED | Stage 2 Cohort 2: Atezolizumab + Cobimetinib | 0 | |
| Stage 1 | STARTED | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q3W | 0 | |
| Stage 1 | STARTED | Stage 2 Cohort 2: Atezolizumab + RO6874281 Q2W | 0 | |
| Stage 1 | Safety Population | Stage 1 Cohort 1 : Control (Chemotherapy: Nab-Paclitaxel and Gemcitabine) | 32 | |
| Stage 1 | Safety Population | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Selicrelumab | 9 | |
| Stage 1 | Safety Population | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + Bevacizumab | 25 | |
| Stage 1 | Safety Population | Stage 1 Cohort 1: Atezolizumab + Chemotherapy + AB928 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03193190/flow